Abood Z, Jan MF, Ashraf M, Kroboth S, Sanders H, Schweitzer M, Misicka A, Ollerman E, Jahangir A, Galazka P, Tajik AJ (2025) Mavacamten in real-life practice: Initial experience at a hypertrophic cardiomyopathy centre. ESC Heart Fail 12:672–676

Article  PubMed  Google Scholar 

Awinda PO, Bishaw Y, Watanabe M, Guglin MA, Campbell KS, Tanner BCW (2020) Effects of mavacamten on Ca(2+) sensitivity of contraction as sarcomere length varied in human myocardium. Br J Pharmacol 177:5609–5621

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borbély A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ (2005) Cardiomyocyte stiffness in diastolic heart failure. Circulation 111:774–781. https://doi.org/10.1161/01.Cir.0000155257.33485.6d

Article  PubMed  Google Scholar 

Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA (2006) Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114:2138–2147. https://doi.org/10.1161/circulationaha.106.632745

Article  PubMed  Google Scholar 

Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM (2010) Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56:845–854

Article  PubMed  PubMed Central  Google Scholar 

Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzky J, Wehri E, Robertson LA, Malik FI, Morgan BP (2021) Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem 64:14142–14152. https://doi.org/10.1021/acs.jmedchem.1c01290

Article  CAS  PubMed  Google Scholar 

Coats CJ, Maron MS, Abraham TP, Olivotto I, Lee MMY, Arad M, Cardim N, Ma CS, Choudhury L, Düngen HD, Garcia-Pavia P, Hagège AA, Lewis GD, Michels M, Oreziak A, Owens AT, Tfelt-Hansen J, Veselka J, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Wohltman A, Masri A (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC Heart Fail 12:199–215. https://doi.org/10.1016/j.jchf.2023.10.004

Article  CAS  PubMed  Google Scholar 

Danzi S, Klein S, Klein I (2008) Differential regulation of the myosin heavy chain genes alpha and beta in rat atria and ventricles: role of antisense RNA. Thyroid 18:761–768

Article  CAS  PubMed  PubMed Central  Google Scholar 

Endoh M (2004) Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol 500:73–86. https://doi.org/10.1016/j.ejphar.2004.07.013

Article  CAS  PubMed  Google Scholar 

Farrant JP, Schmitt M, Reid AB, Garratt CJ, Newman WG, Malhotra A, Beynon R, Mahmod M, Raman B, Cooper RM, Dawson D, Green T, Prasad SK, Singh A, Dodd S, Watkins H, Neubauer S, Miller CA (2025) Considerations for drug trials in hypertrophic cardiomyopathy. ESC Heart Fail 12:1095–1112

Article  PubMed  Google Scholar 

Fuller GA, Bicer S, Hamlin RL, Yamaguchi M, Reiser PJ (2007) Increased myosin heavy chain-beta with atrial expression of ventricular light chain-2 in canine cardiomyopathy. J Card Fail 13:680–686. https://doi.org/10.1016/j.cardfail.2007.05.006

Article  CAS  PubMed  Google Scholar 

Gevaert AB, Winzer EB, Mueller S, De Schutter S, Beckers PJ, Hommel J, Linke A, Wisløff U, Adams V, Pieske B, Halle M, Van Craenenbroeck EM, Van De Heyning CM (2025) Training-induced change of diastolic function in heart failure with preserved ejection fraction. ESC Heart Fail 12:1652–1662

Article  PubMed  PubMed Central  Google Scholar 

Hegyi B, Horváth B, Váczi K, Gönczi M, Kistamás K, Ruzsnavszky F, Veress R, Izu LT, Chen-Izu Y, Bányász T, Magyar J, Csernoch L, Nánási PP, Szentandrássy N (2017) Ca(2+)-activated Cl(-) current is antiarrhythmic by reducing both spatial and temporal heterogeneity of cardiac repolarization. J Mol Cell Cardiol 109:27–37

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, Lambing J, Lee J, Semigran M, Sehnert AJ (2019) Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med 170:741–748. https://doi.org/10.7326/m18-3016

Article  PubMed  Google Scholar 

Heusch G (2022) Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 117:1

Article  PubMed  PubMed Central  Google Scholar 

Heusch G, Neumann T (1998) Calcium responsiveness in canine pacing-induced heart failure. J Mol Cell Cardiol 30:1605–1613. https://doi.org/10.1006/jmcc.1998.0726

Article  CAS  PubMed  Google Scholar 

Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, Waldman CB, Zhang D, Sehnert AJ, Heitner SB (2020) Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail 13:e006853. https://doi.org/10.1161/circheartfailure.120.006853

Article  PubMed  Google Scholar 

Horváth B, Váczi K, Hegyi B, Gönczi M, Dienes B, Kistamás K, Bányász T, Magyar J, Baczkó I, Varró A, Seprényi G, Csernoch L, Nánási PP, Szentandrássy N (2016) Sarcolemmal Ca(2+)-entry through L-type Ca(2+) channels controls the profile of Ca(2+)-activated Cl(-) current in canine ventricular myocytes. J Mol Cell Cardiol 97:125–139. https://doi.org/10.1016/j.yjmcc.2016.05.006

Article  CAS  PubMed  Google Scholar 

Hou L, Lin B, Ji X, Huang A (2025) Cardiac myosin inhibitors in hypertrophic cardiomyopathy: clinical advances and therapeutic prospects. Drug Des Devel Ther 19:9367–9385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huke S, Knollmann BC (2013) Familial hypertrophic cardiomyopathy: is the Frank-Starling law kaput? Circ Res 112:1409–1411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izawa H, Yokota M, Nagata K, Iwase M, Sobue T (1996) Impaired response of left ventricular relaxation to exercise-induced adrenergic stimulation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 28:1738–1745. https://doi.org/10.1016/s0735-1097(96)00378-6

Article  CAS  PubMed  Google Scholar 

Kitzman DW (2002) Diastolic heart failure in the elderly. Heart Fail Rev 7:17–27. https://doi.org/10.1023/a:1013745705318

Article  PubMed  Google Scholar 

Lehman SJ, Crocini C, Leinwand LA (2022) Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol 19:353–363

Article  PubMed  PubMed Central  Google Scholar 

Li Z, Sun X, Wang Y, Zhang F, Wang L, Ai C, Zhang X, Yin X, Liu C, Li C, Lu C (2025) Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis. Basic Res Cardiol 120:1225–1247

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu L, Wang R, Strocchi S, Eroglu T, Nambiar N, Liévano Contreras SV, Diezel SA, Schiattarella GG (2025) Serum amyloid A in HFpEF and cardiometabolic diseases. Basic Res Cardiol. https://doi.org/10.1007/s00395-025-01150-9

Article  PubMed  PubMed Central  Google Scholar 

Lohse MJ, Engelhardt S, Eschenhagen T (2003) What is the role of beta-adrenergic signaling in heart failure? Circ Res 93:896–906. https://doi.org/10.1161/01.Res.0000102042.83024.Ca

Article  CAS  PubMed  Google Scholar 

Ma W, Henze M, Anderson RL, Gong H, Wong FL, Del Rio CL, Irving T (2021) The super-relaxed state and length dependent activation in porcine myocardium. Circ Res 129:617–630

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD (2022) A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci 7:763–775